AbbVie settles Humira biosimilar dispute with Fresenius Kabi
October 18, 2018 at 09:45 AM EDT
U.S. drugmaker AbbVie Inc said on Thursday it has settled a patent dispute regarding its Humira biosimilar with Fresenius Kabi Oncology Ltd and will grant the Germany-based company non-exclusive marketing rights for the drug.